HELSINKI, Finland-Oncos Therapeutics Ltd., a company developing novel cancer immune therapeutics, was nominated among the 20 most promising startup companies in Finland for the second consecutive year. The nomination was made by Talouselämä, the leading Finnish business and economy magazine.
“Finland is a country whose startup hype has traditionally dwelt around game-changing Angry Birdses and global ICT stars. It’s quite an achievement to break a biotech company through to top 20 in such a country – and it’s unheard of to make it twice in a row”, comments Frans Wuite, CEO and President of Oncos. “I am very proud of the continued hard work by our entire team that has made this possible.”
An abstract of the full article in Talouselämä can be found here (in Finnish).
About Oncos Therapeutics
Oncos Therapeutics develops personalized cancer immunotherapeutics based on its proprietary oncolytic adenovirus technology. The Company has clinical experience on 10 purposefully engineered vaccines. These have a direct oncolytic effect due to selective virus replication in tumor cells as well as systemic effects through vascular dissemination to metastases and induction of a strong immune response against tumor cells mediated by exposure of tumor antigens by oncolysis. In addition, most of Oncos product candidates have a transgene that result in cytokine production in only cancer cells, e.g. GM-CSF, further enhancing the immune response against tumor cells. Oncos’ oncolytic vaccine portfolio will be focused on carefully selected cancer types that respond poorly to conventional therapies.
Based on efficacy and safety signals obtained in an Advanced Therapy Access Program (ATAP) with 290 cancer patients, for whom standard of care therapies had failed, CGTG-102 was selected as Oncos’ lead product. Clinical experience with 115 CGTG-102-treated patients in ATAP has yielded important information on e.g. optimal dosing and scheduling of the product. CGTG-102 has an orphan indication as its initial target indication: First line treatment of inoperable Soft Tissue Sarcoma. CGTG-102 is currently in Phase 1 of clinical development in Europe and the United States. For more information please visit www.oncos.com.